drugset
drugset / Trial / NCT05061251

Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma

NCT05061251 ↗

Phase 0 Withdrawn University of Texas Southwestern Medical Center Bayer · collab
NaSingle-groupOpen-labelTreatment

Summary

This study aims to look at how BAY 2402234 responds in body in patients with recurrent glioma.

Timeline

Start
2021-12-01
Primary completion
2022-12-01
Completion
2023-12-01

Outcome

Outcome not reported

Stopped: “Drug availability”

Drugs

EvaluationDrugModalityDoseRoute
Subject BAY2402234 Small molecule 5 mg Oral

Indications

glioma